GD2-Targeting CAR T Cells Show 66% Response Rate in High-Risk Neuroblastoma Trial
Key Insights
Final results from a phase 1/2 trial demonstrate that GD2-targeting CAR T cells achieved a 66% overall response rate in 54 children with high-risk neuroblastoma (search).
Children with low disease burden treated at the recommended dose showed even better outcomes with 77% response rate and 67.6% five-year overall survival.
The CAR T cells exhibited robust expansion and persistence, remaining detectable up to 5 years post-infusion in some patients.
Final results from a groundbreaking phase 1/2 trial published in Nature Medicine (search) demonstrate that GD2-targeting CAR T cells achieved significant clinical responses in children with high-risk neuroblastoma (search), marking a potential breakthrough for CAR T cell therapy in solid tumors. The study, led by Franco Locatelli and colleagues, enrolled 54 children with high-risk metastatic, relapsed, or treatment-refractory neuroblastoma across both the clinical trial and case series.
Clinical Efficacy Results
The trial demonstrated an overall response rate (ORR) of 66% in the clinical trial cohort, with a five-year overall survival of 42.7% (excluding three patients treated with no evidence of disease). Children with low disease burden who received the recommended CAR T dose showed even more promising outcomes, achieving an ORR of 77% and a five-year overall survival of 67.6%. This subgroup included 30 patients across both the trial and case series.
CAR T Cell Persistence and Safety
The GD2-targeting CAR T cells, designated as GD2-CART01, exhibited robust expansion and persistence following infusion. Remarkably, the cells remained detectable up to five years post-infusion in some patients with sufficient follow-up. The study reported no new safety signals beyond those previously identified in the interim analysis published in the New England Journal of Medicine in 2023.
Significance for Solid Tumor Treatment
These results represent a significant advancement for CAR T cell therapy in solid tumors, an area where clinical efficacy has been limited compared to hematological malignancies. Neuroblastoma (search), one of the most common pediatric cancers, expresses high levels of GD2 (search), making it an attractive target for this therapeutic approach. The data particularly support the efficacy of this therapy when administered early in the treatment course.
Future Development
Based on these encouraging results, a larger phase 2 trial is now being planned to validate this therapeutic approach. The study included 35 patients in the formal clinical trial and an additional 19 children treated under hospital exemption with the same criteria, providing a robust dataset for evaluating the therapy's potential.
The research team, including Angela Mastronuzzi from Bambino Gesù Children's Hospital (search), emphasized that these findings showcase the clinical potential for CAR T cells in treating solid tumors, offering new hope for children with this challenging cancer.